Achieve Life Sciences (ACHV) Misses Q3 EPS by 22c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Achieve Life Sciences (ACHV) Misses Q3 EPS by 22c

Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update

November 14, 2022 4:05 PM EST

SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced third quarter 2022 financial results and provided an update on the cytisinicline development program.

Highlights

Completion of targeted enrollment in Phase 3 ORCA-3 clinical trial of cytisinicline in 750 adult smokers was announced in SeptemberEarly completion of targeted enrollment in the Phase 2 ORCA-V1 clinical trial of cytisinicline in 150 adult nicotine e-cigarette users was... More